GENEREX BIOTECHNOL (GNBT)

2.51
0.00 (0.00)
OTC
Prev Close 2.51
Open 2.50
Day Low/High 2.50 / 2.51
52 Wk Low/High 2.16 / 6.00
Volume 5.07K
Exchange OTC
Shares Outstanding 1.06B
Market Cap 2.88M
Div & Yield N.A. (N.A)

Latest News

Generex Announces Initial Pharmacy Acquisitions & Plans For Broader Acquisitions Strategy

Generex Announces Initial Pharmacy Acquisitions & Plans For Broader Acquisitions Strategy

Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.

Generex Confirms Receipt Of $700,000 USD License Fee From Shenzhen BioScien Pharmaceuticals

Generex Confirms Receipt Of $700,000 USD License Fee From Shenzhen BioScien Pharmaceuticals

Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.

Generex Announces Investor Conference Call; Management To Provide Update On Initiatives & Strategic Plans

Generex Announces Investor Conference Call; Management To Provide Update On Initiatives & Strategic Plans

Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.

Generex Announces Upgrade To OTCQB® Venture Market

Generex Announces Upgrade To OTCQB® Venture Market

Generex Biotechnology Corporation (OTCQB:GNBT) ( http://www.otcmarkets.

Generex Announces Results Of Annual Stockholders' Meeting

Generex Announces Results Of Annual Stockholders' Meeting

Generex Biotechnology Corporation (OTCPink:GNBT) ( www.generex.

Generex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® In Chile

Generex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® In Chile

Generex Biotechnology Corporation (OTCPink:GNBT) ( www.generex.

Generex Announces New Clinical Trial Of Hema Diagnostic Systems' Rapid 1-2-3® Tuberculosis Point-of-Care Tests

Generex Announces New Clinical Trial Of Hema Diagnostic Systems' Rapid 1-2-3® Tuberculosis Point-of-Care Tests

Generex Biotechnology Corporation (OTCPink:GNBT) ( www.generex.

Generex Announces Order For Hema Diagnostic Systems' Rapid 1-2-3® Hema HIV EXPRESS® In Chile

Generex Announces Order For Hema Diagnostic Systems' Rapid 1-2-3® Hema HIV EXPRESS® In Chile

Generex Biotechnology Corporation (OTC Pink:GNBT) ( www.generex.

Generex Provides Summary Of Ii-Key Hybrid Vaccine Platform

Generex Provides Summary Of Ii-Key Hybrid Vaccine Platform

Generex Biotechnology Corporation ( www.generex.

Generex Announces Reverse Stock Split

Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000.

Generex Provides Access Information For Investor Conference Call Scheduled For February 22, 2017

Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his...

Generex Announces Elimination Of Outstanding Derivative Securities

Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination of its outstanding derivative securities.

Generex Provides Update On Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences, Inc.

On January 23, 2017 Generex Biotechnology Corporation (OTCPink:GNBT) announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc.

Generex Announces Investor Conference Call

Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it will hold an investor conference call at 10 a.

Generex Announces Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences, Inc.

Generex Announces Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences, Inc.

Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 16, 2017 it entered into a letter of intent (the " LOI") for the acquisition of a controlling equity interest in Emmaus Life Sciences,...

Generex Announces Closing Of Acquisition Of Controlling Equity Interest In Hema Diagnostic Systems

Generex Announces Closing Of Acquisition Of Controlling Equity Interest In Hema Diagnostic Systems

Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 19, 2017 it consummated the previously announced acquisition of a controlling equity interest in Hema Diagnostic Systems, LLC ( www.

Biotech Stock Mailbag: Generex

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Generex Oncology Announces Consultancy Of Dr. George E. Peoples, MD

Cancer Vaccine Specialist to Assist in the On-Going Clinical and Regulatory Development of the Company's Proprietary Breast Cancer Vaccine

Generex Biotechnology Initiates Social Media Campaign For Its Corporate And E-Commerce Websites

Online Efforts Will Focus on Glucose RapidSpray(TM), Crave-NX(TM) Diet Spray, BaBoom!(TM) Energy Spray and Glucose RapidSpray(TM) for Pets(TM)

Generex Biotechnology Creates Scientific Advisory Board To Further The Progression Of Its Drug Development Programs

Anticipates Adding Several Industry Leaders in the Fields of Oncology and Metabolic Science in the Coming Weeks

Generex Announces AGM Results

Generex Provides Positive Update On Generex Oral-Lyn(TM) Pivotal Phase III Trial

Generex Provides Positive Update On Generex Oral-Lyn(TM) Pivotal Phase III Trial

Study Has Now Achieved 75% of the Required Number of Per-Protocol Completers